TPOXX (Tecovirimat-SIGA) was a key component of the global response to the mpox (monkeypox) outbreak

For any inquiries, please contact us at monkeypox@siga.com

TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox

Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus

Named 27th on the Forbes List of Best Small Cap Companies

Health Security

We are a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security.


(Note: TPOXX is approved by the U.S. FDA and Health Canada for the treatment of Smallpox; Tecovirimat-SIGA is approved by the EMA and MHRA for the treatment of monkeypox, cowpox, smallpox, and complications from vaccinia virus)

Our Pipeline

Attractive product and market expansion opportunities

Our Team

Experienced team of scientists and business leaders

Our Partners

Rich history of successful partnerships to support our vision

SIGA Technologies Receives Approval from UK for Tecovirimat

Learn More

News & Press Releases

More News

Health Security is a $12.7 billion market

Medical countermeasures for biological, chemical, radiological and nuclear attacks, as well as vaccines, therapeutics and diagnostics for emerging infectious diseases

  • Corporate Headquarters
    31 East 62nd Street
    New York, NY 10065
    (212) 672-9100

  • SIGA Development Operations
    4575 SW Research Way, Suite 110
    Corvallis, OR 97333
    (541) 753-2000

HCP and Product Inquiries: Call 541-766-3744

© 2023 SIGA Technologies, All Rights Reserved